Free Trial

Johnson & Johnson (JNJ) Expected to Announce Quarterly Earnings on Wednesday

Johnson & Johnson logo with Medical background

Johnson & Johnson (NYSE:JNJ - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 16th. Analysts expect the company to announce earnings of $2.65 per share and revenue of $22.85 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Stock Down 0.5%

Shares of Johnson & Johnson stock traded down $0.82 during trading on Friday, hitting $156.87. 7,866,488 shares of the stock were exchanged, compared to its average volume of 8,077,942. The stock has a market cap of $377.44 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. The firm's 50-day moving average price is $153.75 and its 200 day moving average price is $154.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.

Hedge Funds Weigh In On Johnson & Johnson

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,876 shares of the company's stock after purchasing an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 as of its most recent filing with the Securities and Exchange Commission. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $171.00.

Read Our Latest Stock Analysis on Johnson & Johnson

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Further Reading

Earnings History for Johnson & Johnson (NYSE:JNJ)

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines